APA
Click to copy
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., … Shen, A.-Z. (2019). Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics.
Chicago/Turabian
Click to copy
Feng, Xiaojun, A. Sureda, S. Jafari, Zahra Memariani, Devesh Tewari, G. Annunziata, L. Barrea, et al. “Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.” Theranostics (2019).
MLA
Click to copy
Feng, Xiaojun, et al. “Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.” Theranostics, 2019.
BibTeX Click to copy
@article{xiaojun2019a,
title = {Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics},
year = {2019},
journal = {Theranostics},
author = {Feng, Xiaojun and Sureda, A. and Jafari, S. and Memariani, Zahra and Tewari, Devesh and Annunziata, G. and Barrea, L. and Hassan, Sherif T.S. and Šmejkal, K. and Malaník, Milan and Sychrová, Alice and Barreca, D. and Žiberna, L. and Mahomoodally, M. and Zengin, G. and Xu, Suowen and Nabavi, S. and Shen, Ai-Zong}
}
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.